Literature DB >> 17132599

Physicians' opinions and experiences of the Pharmaceutical Benefits Reform.

Karolina Andersson1, Tove Jörgensen, Anders Carlsten.   

Abstract

AIM: To investigate opinions on and experiences of the new Pharmaceutical Benefits Reform (PBR) among physicians working in the Swedish county council of Region Västra Götaland.
METHODS: Questionnaires were sent to all private practitioners who had contracts with the county council of Region Västra Götaland (n = 320) and a random sample of 25% of the doctors employed by the same county council (n = 1,068). The questionnaire comprised questions on how the physicians had received information on the PBR and sought opinions on the introduction of generic substitution in pharmacies, workplace codes, individual prescriber codes, and the Pharmaceutical Benefits Board. Analyses were performed with logistic regression.
RESULTS: The response rate was 65%. The majority of doctors had received sufficient information about the reform, most often from their employer, followed by the Drug and Therapeutics Committees. More than half of the respondents were positive about the introduction of generic substitution, which was associated with the respondent's age, experiences, and employer. Most of the doctors thought that generic substitution could reduce the health system's pharmaceutical expenditure, which was associated with the employer. One-third reported that generic substitution had caused problems for their patients in the past month. The probability of being mainly positive towards the newly created Pharmaceutical Benefits Board, which decides on reimbursement, increased with increasing age.
CONCLUSIONS: Most participating doctors had received sufficient information about the reform and thought that generic substitution could save money for society. Age, employer, and experiences appeared to influence opinions on several issues.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17132599     DOI: 10.1080/14034940600551111

Source DB:  PubMed          Journal:  Scand J Public Health        ISSN: 1403-4948            Impact factor:   3.021


  6 in total

Review 1.  Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.

Authors:  Brian Godman; Alan Haycox; Ulrich Schwabe; Roberta Joppi; Silvio Garattini
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

2.  Prescribing behaviour after the introduction of decentralized drug budgets: is there an association with employer and type of care facility?

Authors:  Karolina Andersson; Anders Carlsten; Tove Hedenrud
Journal:  Scand J Prim Health Care       Date:  2009       Impact factor: 2.581

3.  The association between automatic generic substitution and treatment persistence with oral bisphosphonates.

Authors:  O Ström; E Landfeldt
Journal:  Osteoporos Int       Date:  2011-11-26       Impact factor: 4.507

4.  Drug Brand Response and Its Impact on Compliance and Efficacy in Depression Patients.

Authors:  Mingming Li; Jian Cai; Ping Zhang; Chunhua Fei; Feng Xu
Journal:  Front Pharmacol       Date:  2017-01-10       Impact factor: 5.810

5.  Norwegian physicians' knowledge of the prices of pharmaceuticals: a survey.

Authors:  Ida Iren Eriksen; Hans Olav Melberg; Berit Bringedal
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

Review 6.  Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review.

Authors:  Sarah Colgan; Kate Faasse; Leslie R Martin; Melika H Stephens; Andrew Grey; Keith J Petrie
Journal:  BMJ Open       Date:  2015-12-15       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.